Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Depreciation & Amortization (CF): 2013-2024

Historic Depreciation & Amortization (CF) for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to $6.4 million.

  • Zevra Therapeutics' Depreciation & Amortization (CF) fell 75.76% to $392,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 3.40%. This contributed to the annual value of $6.4 million for FY2024, which is 535.09% up from last year.
  • Zevra Therapeutics' Depreciation & Amortization (CF) amounted to $6.4 million in FY2024, which was up 535.09% from $1.0 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Depreciation & Amortization (CF) ranged from a high of $6.4 million in FY2024 and a low of $257,000 during FY2021.
  • Over the past 3 years, Zevra Therapeutics' median Depreciation & Amortization (CF) value was $1.0 million (recorded in 2023), while the average stood at $2.8 million.
  • Per our database at Business Quant, Zevra Therapeutics' Depreciation & Amortization (CF) decreased by 10.20% in 2020 and then soared by 535.09% in 2024.
  • Zevra Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $273,000 in 2020, then decreased by 5.86% to $257,000 in 2021, then soared by 267.32% to $944,000 in 2022, then increased by 6.57% to $1.0 million in 2023, then soared by 535.09% to $6.4 million in 2024.